AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04673617 |
|
Recruitment Status :
Recruiting
First Posted : December 17, 2020
Last Update Posted : February 13, 2024
|
Sponsor:
Artiva Biotherapeutics, Inc.
Information provided by (Responsible Party):
Artiva Biotherapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | November 2024 |
| Estimated Study Completion Date : | November 2024 |